Ducap cell line. DuCap is a human prostate … .

Ducap cell line. b DuCaP A new human prostate adenocarcinoma cell line (DuPro-1) has been established from the athymic nude mouse supported xenograft DU5683. ZERO BIAS - scores, article reviews, protocol conditions and more These results indicate the possible presence of stem-like cells in several established PCa cell lines. Comparative RNA-seq expression analysis confirmed the prostatic lineage of the four cell lines, with a distinct gene expression profile from that of the metastatic prostate The TMPRSS2-ERG expressing DuCaP-N cell line represents human prostate cancer prior to endocrine treatment, and its parental DuCaP cell line is a model for CRPC. Cell line DuCaP - associated with prostate, NS, carcinoma | Cell-line overview, RNA Interventions, Copy Number Alterations, Drug Sensitivity, Similar cell lines | canSAR. Out of 35 parallel cultures per cell line, a total of 24, 15, 34, and 16 CRPC sublines emerged for VCaP, DuCaP, PC346C, and LAPC4, respectively. In addition, we measured cell viability and analyzed stem cell marker We performed comparative proteome analyses on ENZA‐sensitive parental (LAPC4, DuCaP) and ‐resistant prostate cancer cell lines (LAPC4‐ENZA, DuCaP‐ENZA) using liquid Description: CRPC DuCap cell line series - source (source cell line from which sublines were made resistant to Bicalutamide through long-term passaging). DuCap is a human prostate . Name:DuCaP Cell Line 中文名称: Organism种属: Comments: Brain met; derived from same patient as VCaP Cell Type细胞类型: Morphology形态: Culture Properties培养特性: Disease疾 DuCaP (a CRPC cell line that has high AKR1C3 expression levels) used and converted DHEA under hormone-depleted conditions into T Model: Tumour Cell Line Model description: CRPC model Receptors of note: Androgen receptor Description: CRPC DuCap cell lines (2 sublines made resistant to Bicalutamide through long Concomitantly, the transfection of synthetic miR-454-3p reduced the protein expression of AR in both EnzR cell lines and that of c-Myc and AR-V7 in the DuCaP EnzR cell Cell line DuCaP - associated with prostate, NS, carcinoma | Cell-line overview, RNA Interventions, Copy Number Alterations, Drug Sensitivity, Similar cell lines | canSAR. ZERO BIAS - scores, article reviews, protocol conditions and more To assess the biological relevance of CYP17A1‐mediated cell growth in CRPC, we selected CRPC cell lines of VCaP (BIC‐B and FLU‐D, We sought to establish a panel of prostate cancer cell lines that could capture some of the clinical heterogeneity observed in prostate cancers. Molecular characterization and critical appraisal of human prostate carcinoma cell lines. CD133 selection does not enrich for stem-like cells in PCa cell lines. Bioz Stars score: 86/100, based on 1 PubMed citations. This was accomplished by Our work provides a resource for genetic, genomic, and biological studies employing these commonly-used prostate cancer cell lines. Thus, the AR expressing cell lines DuCaP and 22Rv1 cells were selected. Here we report Description: CRPC DuCap cell line series - source (source cell line from which sublines were made resistant to Bicalutamide through long-term passaging). a PC-3 cell line. Prostate cancer cell lines are essential tools to understanding Description: CRPC DuCap cell line series - source (source cell line from which sublines were made resistant to Bicalutamide through long-term passaging). DuCap is a human prostate Ducap Cell Lines, supplied by ATCC, used in various techniques. 9 μm by day 8. ai Out of 35 parallel cultures per cell line, a total of 24, 15, 34, and 16 CRPC sublines emerged for VCaP, DuCaP, PC346C, and LAPC4, respectively. This cell line is subclone H. ai These cell lines can be used to study the role of AR signalling and mechanisms of resistance to androgen deprivation therapy and AR targeting agents in CRPC. The full panel of cell lines that We performed comparative proteome analyses on ENZA‐sensitive parental (LAPC4, DuCaP) and ‐resistant prostate cancer cell lines (LAPC4‐ENZA, DuCaP‐ENZA) NCBI's Gene Expression Omnibus (GEO) is a public archive and resource for gene expression data. DuCap is a human prostate The lack of appropriate, clinically relevant, cell-based model systems has limited prostate cancer research and the development of new therapeutic modalities. Csizmarik A, et al. The addition of bicalutamide Representative images for EpCAM expression in CaP cell line, spheroids, xenografts, tissues and lymph node metastases. DuCaP cells formed compact irregular-shaped spheroids with a mean radius of 462. DuCaP cells were derived from a metastatic lesion to the dura mater of a patient with Gene expression profiles were determined by microarray or qRT-PCR. Notably, the formation of DuCaP spheroids was temporally delayed Ducap Cell Lines, supplied by ATCC, used in various techniques. DuCap is a human prostate cancer cell line that expresses wild-type androgen receptor (AR), this cell line has been used as a model to study AR signalling in prostate cancer. Prostate cancer tissue was Our current knowledge regarding the mechanisms of anti-androgen resistance in PCa mostly derives from in vitro studies using AR-positive PCa cell lines such as LNCaP, Prostate cancer is a broad-spectrum disease, spanning from indolent to a highly aggressive lethal malignancy. DuCap is a human prostate Description: CRPC DuCap cell line series - source (source cell line from which sublines were made resistant to Bicalutamide through long-term passaging). (2022) Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate Integrative genomic view of the PTPRK locus showing evidence of binding of TE close to promoter regions (hg19, chr6:128,861,959−128,862,733) from VCaP cell line. The DuCap 2 [BIC B] CRPC Cell line: part of CRPC DuCap cell lines (2 sublines made resistant to Bicalutamide through long-term passaging) - Bicalutamide B. Here we report the isolation and characterization of a new adherent prostate cancer cell line, derived from the dura mater of a cancer patient. 3 ± 14.